DelveInsight’s “Food Allergy Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the food allergy, historical and forecasted epidemiology and the food allergy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Unlock key insights into the Food Allergy Market! Download DelveInsight’s comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Food Allergy Market Size

 

Key Takeaways from the Food Allergy Market Report

• In January 2025:- ALK-Abello A/S:- This is a phase I/II, dose-escalation, multi-site trial including subjects with peanut allergy confirmed by screening double-blind, placebo-controlled food challenge. The trial is conducted in 3 parts; part 1 will determine the entry dose of the up-dosing regimen (UDR) in adults and adolescents; part 2 will characterize the tolerability of the up-dosing regimen in adults, adolescents and children; part 3 will evaluate the efficacy of 2 maintenance doses of the SLIT-tablet primarily in adolescents and children; a small number of adults may also be included.
• DelveInsight’s analyst estimate that approximately 57.5 million Prevalent Cases of Food Allergy were found in 2023 in the 7MM.
• The United States exhibited the highest diagnosed prevalent population of food allergy, as compared to other 7MM countries. As per DelveInsight’s estimations, the Total Prevalent Cases of Food Allergy in the US was around 33.1 million in 2023 and is projected to increase during the forecast period owing to the increasing awareness among the patient population and launch of novel therapies.
• According to DelveInsight’s estimates, the Total Prevalent Cases of Food Allergy in EU4 and the UK were found to be ~16.9 million in 2023. Throughout the study period, it is anticipated that there will be a substantial increase in cases for all contributing countries, except for Germany, where the cases are expected to decrease. The highest proportion of Food Allergy cases was reported in Spain among the EU4 countries, while the least number of cases was found in the UK.
• The estimates show the Total Prevalent Cases of Food Allergy in Japan was found to be around 7.4 million in 2023, which is estimated to decrease by 2034.
• In the US, food allergy cases were classified by specific causes such as Cow Milk, Peanut, Eggs, Wheat, Treenuts, Fish, Shellfish, Soy, and Others. Shellfish accounted for the most prevalent cases, approximately 8 million, in 2023.
• According to the analysis performed by DelveInsight’s experts, the Age-specific Cases of Food Allergy were categorized into Children, and Adults. The higher number of cases (~28 million) was accounted for by the Adults in 2023 in the US.
• The leading Food allergy Companies such as Aimmune Therapeutics, Inc., Novartis, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company Inc., Vedanta Biosciences, Inc., Regeneron Pharmaceuticals, Genentech, Inc., Rho Federal Systems Division, Inc., Alladapt Immunotherapeutics, Inc., Camallergy, and others.
• Promising Food allergy Therapies such as Ligelizumab 120 mg, Dupilumab, Omalizumab, and others.

 

Stay ahead in the competitive landscape of the Food Allergy Market. Access DelveInsight’s in-depth market analysis and strategic insights today! Click here for more @ Food Allergy Treatment Market Size

 

Food Allergy Epidemiology Segmentation in the 7MM

• Total Prevalent cases of Food Allergy
• Etiology-specific cases of Food Allergy
• Age-specific cases of Food Allergy

 

Download the report to understand which factors are driving Food Allergy epidemiology trends @ Food Allergy Prevalence

 

Food Allergy Marketed Drugs

• Palforzia: Aimmune Therapeutics, Inc.

Approved in 2020, Palforzia is a complex biologic drug used with a structured dosing approach that builds on a century of oral immunotherapy (OIT) research. With OIT, the specific allergenic proteins are ingested initially in very small quantities, followed by incrementally increasing amounts, resulting in the ability to mitigate allergic reactions to the allergen over time. Palforiza is the first approved treatment for patients with peanut allergy. It is oral immunotherapy indicated to mitigate allergic reactions, including anaphylaxis that may occur with accidental exposure to peanuts. Palforzia is approved for use in patients with a confirmed diagnosis of peanut allergy.

 

Food Allergy Emerging Drugs

• Ligelizumab: Novartis Pharmaceuticals

Ligelizumab (QGE031), a humanized anti-IgE antibody developed by Novartis, is a next-generation monoclonal anti-immunoglobulin E (IgE) antibody. It is also directed against Cε3, but is designed to achieve improved IgE suppression, with an equilibrium dissociation constant (KD) of 139 pM (as compared to the KD of omalizumab, ~6–8 nm). Ligelizumab’s mechanism of action involves blocking the IgE/FcεRI pathway, a key driver of the inflammatory process in CSU (chronic spontaneous urticaria), and binding with high affinity to the Cε3 domain of IgE.

 

• Viaskin Peanut: DBV Technologies

Viaskin Peanut is the first epicutaneous immunotherapy (EPIT) in development that leverages the skin to activate the immune system and induce desensitization in peanut-allergic children. EPIT aims to target specific epidermal dendritic cells, called Langerhans cells. Pre-clinical research has shown that these cells capture antigens and migrate to the lymph node in order to activate the immune system. By delivering the allergen directly to the lymph node through the Langerhans cells, pre-clinical research has shown that EPIT activates specific regulatory T cells (Tregs) that can down-regulate the Th2-oriented reaction to the allergen.

 

Discover the future of Food Allergy Treatments with DelveInsight’s latest market report. Get expert insights and forecasts—download now! @ Food Allergy Market Drivers and Barriers

 

Food Allergy Market Outlook

Food allergy has a diverse treatment classification associated with the disease landscape. The management of food allergy primarily revolves around the utilization of Epinephrine, Anti-histamines, Steroids, Beta-2-agonists, and Palforzia as needed. Palforzia is the major revenue generator in the current treatment landscape. The market for food allergy is expected to experience positive growth with the approval of potential drugs like Ligelizumab (QGE031), Viaskin Peanut, Omalizumab, and others.

 

Food Allergy Treatment Market Landscape

Food Allergy treatment is a rapidly changing landscape, with arguably, the most significant advancement in recent years, the transition of oral immunotherapy (OIT) to clinical practice. As an innovation, OIT is a phase of rapidly increasing demand, particularly for some allergens such as peanut, egg, and milk, which have substantial evidence of efficacy. The only proven medication therapy against a food allergy is strict elimination of the offending food allergen from the diet. The primary care of treatment, including antihistamines, injectable epinephrine, and immunotherapies is prescribed to patients with mild, and moderate to severe cases of Food Allergy. Injectable epinephrine is the drug of choice for the initial management of a food-induced anaphylactic reaction. In severe anaphylaxis, ventilatory and circulatory support may be needed.

 

Explore the dynamics of the Food Allergy Market with DelveInsight. From market size to emerging drugs—find it all in our latest report. Read now! @ Food Allergy Ongoing Clinical Trials Analysis

 

Scope of the Food Allergy Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Food Allergy Companies- Aimmune Therapeutics, Inc., Novartis, DBV Technologies, InnoUp Farma S.L., COUR Pharmaceutical Development Company Inc., Vedanta Biosciences, Inc., Regeneron Pharmaceuticals, Genentech, Inc., Rho Federal Systems Division, Inc., Alladapt Immunotherapeutics, Inc., Camallergy, and others.
• Food allergy Therapies- Ligelizumab 120 mg, Dupilumab, Omalizumab, and others.
• Food Allergy Market Dynamics: Food Allergy Market drivers and Food Allergy Market Barriers
• Food Allergy Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Food Allergy Unmet Needs, KOL’s views, Analyst’s views, Food Allergy Market Access and Reimbursement

 

Table of Content

1 Key Insights

2 Report Introduction

3 Food Allergy Market Overview at a Glance

4 Methodology of Food Allergy Epidemiology and Market

5 Executive Summary of Food Allergy

6 Key Events

8 Epidemiology and Patient Population

9 Patient Journey

10 Marketed Therapies

11 Emerging Drugs

12 Food Allergy: Seven Major Market Analysis

13 KOL Views

14 SWOT Analysis

15 Unmet Needs

16 Market Access

17 Appendix

18 DelveInsight Capabilities

19 Disclaimer

20 About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market